Schrodinger (SDGR) stock

Molecule software , market cap $2.2B

Molecule software

Worth $2.2B

$32.41

-2.94%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#20of 90

Pharma

Checks firing

6of 14

Trending up

From 52-week high

-4.1%

under its best in a year

SDGR's Quality Score fell 3 points on Tue, Nov 10, to 9. Buying slipped from its highest in 20 days (3 chart checks stopped).

See SDGR's 14 chart checksSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why SDGR rose this week

Up 28% over the five sessions to Nov 9 while the S&P 500 rose 0.1%.

It rose 0.9% on Nov 5, the session after its Nov 4 results, which raised the drug discovery revenue outlook to $75M to $85M.

Sources: Price history, Nov 9, 2026; Company release, Nov 4, 2026

1 more reason, free with an account →4 more reasons why SDGR rose this week, from its filings, with the other side, the company's words, the timeline, and its peers, for Pro members.

Key facts on SDGR

Key facts on SDGR
The chart	Stronger than 99% of stocks above every average
Latest filing	8-K, Nov 4 Reported its quarterly results

1 more reason behind SDGR's 9, free with an account →2 more reasons behind SDGR's 9, for Pro members.

SDGR in the news

Wed Nov 4Schrodinger reported quarterly revenue of $64.5 million and a diluted loss of $0.50 a share SEC, 4:06 PM ET SDGR closed +0.9% the next session (Nov 5).

What's next

Tue Nov 10: UBS Global Healthcare Conference 2026Investor conference · date confirmed.

SDGR catalysts

Coming up

After its last 4 reports it closed +4.6% on average, higher 4 of 4 times.

22 past catalysts since 2021, with sizes and sources, for Pro members.

Why SDGR scores 9

Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means

+6Chart checks 6 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Profit, Growth, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on SDGR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when SDGR's Quality Score turns up

A free account. No card.

How SDGR ranks in Pharma

SDGR is #20 of 90 by Quality Score.

How SDGR ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	10/14	23
2	LLYEli Lilly	8/14	21
3	PFEPfizer	6/14	17
	RDYDr. Reddy's Laboratories		Open for its score
	ROIVRoivant Sciences		Open for its score
	SIGASIGA Technologies		Open for its score
	SLSSELLAS Life Sciences		Open for its score
20	SDGRSchrodinger	6/14	9

Free cash flow over four quarters: SDGR -$117M, PTCT $2.07M, LGND $90.6M.

When does SDGR report earnings, and what happens after?

Expected to report Wed Feb 24, after the close (in 106 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What SDGR reported on Nov 4, 2026

The quarter

Sales of $64.5M, 19% more than a year ago; a loss of $0.50 a share, from $0.45.

“Drug discovery revenue was $24.2 million compared to $13.0 million, primarily due to the recognition of a milestone payment from Structure Therapeutics.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Software Products and Servicesup 6.2%	$38.2M59%	$32.5M52%	$35.9M66%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 4)

14 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Fiscal year ending December 31, 2026
Drug discovery revenue	$75M to $85Mraised

Figures as filed (SEC filing, Nov 4)

2 more outlook lines, for Pro members.

The numbers

Market value: $2.2B; today
Sales: $269M; up 4.8% on the year
Free cash flow: -$117M; last 12 months

Sales grew 19% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 4.1% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on SDGR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+8.1%+0.8%+8.6%+0.9%

Feb 25May 5Aug 5Nov 4

Reported	When	Gap	Reaction	5 days
Nov 4, 2026After close	After close	+2.0%	+0.9%	not yet
Aug 5, 2026After close	After close	+5.3%	+8.6%	+13.6%
May 5, 2026After close	After close	-5.4%	+0.8%	-1.4%
Feb 25, 2026After close	After close	+10.2%	+8.1%	+11.2%

SDGR closed higher after 4 of its last 4 reports.

SDGR sales and profit by year

Sales and profit by year

Sales grew in four of the last five years, to $256M in 2025. It made a profit in one of the six years.

SDGR has 6 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on SDGR, and all 14 on every stock.Get in free →

SDGR RSI today: 63.4, above its 50-day and 200-day averages

Not scored

RSI 63.4, MACD above signal, above both averages. Not scored.13 readings

The deep dive on SDGR

What it does and how it makes money6 findings"We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones … and royalties under our collaboration agreements." (10-K for fiscal 2025)SEC filing · Feb 25, 2026"Our obligation to pay any royalty under the 2001 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, terminated with the expiration of the last to expire patent licensed under the 2001 Columbia Agreement in January 2014." (10-K for fiscal 2025)SEC filing · Feb 25, 2026
Where it stands3 findingsFor Pro members3 findings on where SDGR stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"Subsequently, other parties, including the U.S. Chamber of Commerce and other pharmaceutical companies also filed lawsuits in various courts with similar constitutional claims against HHS and CMS." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 4, 2026One customer made up 17% of its revenue in fiscal 2025, up from 10% in fiscal 2024.SEC filing · Feb 25, 2026Backlog rose 251% in a year, to $187M on Sep 30, 2026 from $53.2M: sales under contract, not yet delivered. "The Company expects to recognize as revenue approximately 62 % of its September 30, 2026 remaining performance obligations in the next 12 months and the remainder thereafter."SEC filing · Nov 4, 2026
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades SDGR, for Pro members
Against its closest peers2 peersFree cash flow over four quarters: SDGR -$117M, PTCT $2.07M, LGND $90.6M.

9 more findings on SDGR, each with its source, for Pro members.

SDGR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Ramy FaridPresident & CEO · 4 trades
Rachit JainEVP & CFO · 3 trades
Jenny HermanCAO · 3 trades
Karen AkinsanyaOfficer · 3 trades
Yvonne TranEVP, CLO & CPO · 3 trades
Kenneth Patrick LortonEVP, CTO & COO, Software · 2 trades
Robert Lorne AbelOfficer · 2 trades
Mannix Vartan AklianOfficer · no trades on file

9 more officers and directors file at SDGR.

See insider trades by person

About Schrodinger

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

850 employeesNew York, NYschrodinger.com

What Schrodinger says it competes with

“We also face competition from solutions that biopharmaceutical companies develop internally, smaller companies that offer products and services directed at more specific markets than we target, enabling these competitors to focus a greater proportion of their efforts and resources on these markets.”

From its annual report, SEC filing · Feb 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on SDGR and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move SDGR's score: 7 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

See SDGR's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: SDGR's Quality Score is 9 (Average), #20 of 90 in Pharma.

What does SDGR's Quality Score say?

SDGR scores 9 today, which Breakaway calls Average. It is #20 of 90 in Pharma by Quality Score, with 6 of 14 chart checks firing. Up 28% over the five sessions to Nov 9 while the S&P 500 rose 0.1%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SDGR's Quality Score?

SDGR scores 9 today, which Breakaway calls Average (6 to 10). That is #20 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SDGR's 9.

When does SDGR report earnings?

Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. SDGR closed higher after 4 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.